Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leon Aarons

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Clinical Pharmacology|July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 18, 2023
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathwayDavid Hodson, Hitesh Mistry, Sofia Guzzetti, et al.
British Journal of Clinical Pharmacology|February 21, 2006
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsoneJulie A Simpson, Dyfrig Hughes, Christine Manyando, et al.
Basic & Clinical Pharmacology & Toxicology|August 19, 2009
Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual frameworkSvein G Dahl, Leon Aarons, Ursula Gundert-Remy, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Clinical Pharmacokinetics|May 6, 2023
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in ChildrenYumi Cleary, Heidemarie Kletzl, Paul Grimsey, et al.
Clinical Pharmacokinetics|March 25, 2018
The Influence of Normalization Weight in Population Pharmacokinetic Covariate ModelsSebastiaan C Goulooze, Swantje Völler, Pyry A J Välitalo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 14, 2005
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?Ferdinand Rombout, Leon Aarons, Mats Karlsson, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 15, 2010
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging studyJames Galea, Kayode Ogungbenro, Sharon Hulme, et al.
The Journal of Antimicrobial Chemotherapy|February 12, 2005
Pharmacokinetic studies of linezolid and teicoplanin in the critically illTony Whitehouse, Jorge A Cepeda, Rob Shulman, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Clinical Pharmacology|July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 18, 2023
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathwayDavid Hodson, Hitesh Mistry, Sofia Guzzetti, et al.
British Journal of Clinical Pharmacology|February 21, 2006
Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsoneJulie A Simpson, Dyfrig Hughes, Christine Manyando, et al.
Basic & Clinical Pharmacology & Toxicology|August 19, 2009
Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual frameworkSvein G Dahl, Leon Aarons, Ursula Gundert-Remy, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Clinical Pharmacokinetics|May 6, 2023
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in ChildrenYumi Cleary, Heidemarie Kletzl, Paul Grimsey, et al.
Clinical Pharmacokinetics|March 25, 2018
The Influence of Normalization Weight in Population Pharmacokinetic Covariate ModelsSebastiaan C Goulooze, Swantje Völler, Pyry A J Välitalo, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 14, 2005
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?Ferdinand Rombout, Leon Aarons, Mats Karlsson, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 15, 2010
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging studyJames Galea, Kayode Ogungbenro, Sharon Hulme, et al.
The Journal of Antimicrobial Chemotherapy|February 12, 2005
Pharmacokinetic studies of linezolid and teicoplanin in the critically illTony Whitehouse, Jorge A Cepeda, Rob Shulman, et al.
Pageof 13